

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse CD200 R1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 5% cross-reactivity with recombinant human CD200 R is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse CD200 R1 Thr26-Pro238 Accession # BAE42266
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Mouse CD200 R1 Fc Chimera (Catalog # 2554-CD)
Flow Cytometry	2.5 µg/10 ⁶ cells	MC/9-2 mouse masT cell line
Immunocytochemistry	5-15 µg/mL	See Below
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

DATA

Immunocytochemistry



CD200 R1 in Mouse Splenocytes.
CD200 R1 was detected in immersion fixed mouse splenocytes using Goat Anti-Mouse CD200 R1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2554) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for [Fluorescent ICC Staining of Non-adherent Cells](#).

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

CD200 R1, also known as OX-2 receptor, is a 90 kDa, type I transmembrane protein that belongs to the immunoglobulin superfamily. CD200 R1 is important in the regulation of myeloid cell activity (1-3). The mouse CD200 R1 cDNA encodes a 326 aa precursor that includes a 25 aa signal sequence, a 213 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 67 aa cytoplasmic domain. The ECD is composed of one Ig-like V-type domain and one Ig-like C2-type domain (4). Within the ECD, mouse CD200 R1 shares 56% and 70% aa sequence identity with human and rat CD200 R1, respectively. The ECD of mouse CD200 R1 shares 69%, 38%, 79%, and 83% aa sequence identity with the ECD of CD200 R2, 3, 4, and a CD200 R-like molecule, respectively. CD200 R1 is expressed primarily on mast cells, basophils, macrophages, and dendritic cells, (5-7) while its ligand, CD200, is widely distributed (8). Disruption of this receptor-ligand pair by knockout of the CD200 gene leads to increased macrophage number and activation, plus a predisposition to autoimmune disorders (9). Association of CD200 with CD200 R1 takes place between their respective N-terminal Ig-like domains (10). The CD200 R-like molecules may interact differently with CD200 (11, 12). The cytoplasmic domain of CD200 R1 contains two non-ITIM tyrosine residues which are required for propagating its inhibitory signals (13-15). CD200 R-like molecules, in contrast, are potentially activating receptors by means of their association with DAP12 (4, 16).

References:

1. Rosenblum, M.D. *et al.* (2006) *J. Dermatol. Sci.* **41**:165.
2. Gorczynski, R.M. (2005) *Curr. Opin. Invest. Drugs* **6**:483.
3. Barclay, A.N. *et al.* (2002) *Trends Immunol.* **23**:285.
4. Wright, G.J. *et al.* (2003) *J. Immunol.* **171**:3034.
5. Shiratori, I. *et al.* (2005) *J. Immunol.* **175**:4441.
6. Cherwinski, H.M. *et al.* (2005) *J. Immunol.* **174**:1348.
7. Fallarino, F. *et al.* (2004) *J. Immunol.* **173**:3748.
8. Wright, G.J. *et al.* (2001) *Immunology* **102**:173.
9. Hoek, R.M. *et al.* (2000) *Science* **290**:1768.
10. Hatherley, D. and A.N. Barclay (2004) *Eur. J. Immunol.* **34**:1688.
11. Hatherley, D. *et al.* (2005) *J. Immunol.* **175**:2469.
12. Gorczynski, R. *et al.* (2004) *J. Immunol.* **172**:7744.
13. Zhang, S. and J.H. Phillips (2006) *J. Leukoc. Biol.* **79**:363.
14. Zhang, S. *et al.* (2004) *J. Immunol.* **173**:6786.
15. Jenmalm, M.C. *et al.* (2006) *J. Immunol.* **176**:191.
16. Voehringer, D. *et al.* (2004) *J. Biol. Chem.* **279**:54117.